The Friedewald formula underestimates LDL cholesterol at low concentrations

被引:106
作者
Scharnagl, H [1 ]
Nauck, M [1 ]
Wieland, H [1 ]
März, W [1 ]
机构
[1] Univ Freiburg, Dept Med, Div Clin Chem, D-79106 Freiburg, Germany
关键词
Friedewald formula; LDL cholesterol; atherosclerosis;
D O I
10.1515/CCLM.2001.068
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Due to recent advances in the treatment of hypercholesterolemia, low density lipoprotein (LDL) cholesterol concentrations below 2.6 mmol/l have become attainable. In general, LDL cholesterol is determined indirectly according to Friedewald. We examined the performance of the Friedewald formula at low concentrations of LDL cholesterol in comparison with a P-quantification method. We analyzed 176 samples from individuals treated by LDL apheresis with a mean LDL cholesterol concentration of 3.07 mmol/l end found that the Friedewald formula underestimated LDL cholesterol with a bias of -18.5%, -14.5%, -7.3%. and 3.8% at mean LDL cholesterol levels of 1.58, 2.4, 3.49, and 4.67 mmol/l, respectively. Thus, the lower the LDL cholesterol concentration was, the greater the negative bias. We conclude that the Friedewald formula may not be reliable at low LDL cholesterol concentrations produced by LDL apheresis. This finding may also be of relevance to the monitoring of patients being treated with lipid lowering drugs.
引用
收藏
页码:426 / 431
页数:6
相关论文
共 34 条
[21]  
Nauck M, 1997, CLIN CHEM, V43, P1622
[22]  
Packard CJ, 1998, CIRCULATION, V97, P1440
[23]  
PASSING H, 1984, J CLIN CHEM CLIN BIO, V22, P431
[24]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[25]   Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study [J].
Pedersen, TR ;
Olsson, AG ;
Færgeman, O ;
Kjekshus, J ;
Wedel, H ;
Berg, K ;
Wilhelmsen, L ;
Haghfelt, T ;
Thorgeirsson, G ;
Pyörälä, K ;
Miettinen, T ;
Christophersen, B ;
Tobert, JA ;
Musliner, TA ;
Cook, TJ .
CIRCULATION, 1998, 97 (15) :1453-1460
[26]   Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease [J].
Pitt, B ;
Waters, D ;
Brown, WV ;
van Boven, AJ ;
Schwartz, L ;
Title, LM ;
Eisenberg, D ;
Shurzinske, L ;
McCormick, LS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (02) :70-76
[27]  
RIFAI N, 1992, CLIN CHEM, V38, P150
[28]   CALCULATED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL SHOULD NOT BE USED FOR MANAGEMENT OF LIPOPROTEIN ABNORMALITIES IN PATIENTS WITH DIABETES-MELLITUS [J].
RUBIESPRAT, J ;
REVERTER, JL ;
SENTI, M ;
PEDROBOTET, J ;
SALINAS, I ;
LUCAS, A ;
NOGUES, X ;
SANMARTI, A .
DIABETES CARE, 1993, 16 (08) :1081-1086
[29]  
Sacks FM, 1998, CIRCULATION, V97, P1446
[30]   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [J].
Sacks, FM ;
Pfeffer, MA ;
Moye, LA ;
Rouleau, JL ;
Rutherford, JD ;
Cole, TG ;
Brown, L ;
Warnica, JW ;
Arnold, JMO ;
Wun, CC ;
Davis, BR ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1001-1009